Cargando…

The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review

Cell-free DNA profiling using patient blood is emerging as a non-invasive complementary technique for cancer genomic characterization. Since these liquid biopsies will soon be integrated into clinical trial protocols for pediatric cancer treatment, clinicians should be informed about potential appli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Paemel, Ruben, Vlug, Roos, De Preter, Katleen, Van Roy, Nadine, Speleman, Frank, Willems, Leen, Lammens, Tim, Laureys, Geneviève, Schleiermacher, Gudrun, Tytgat, Godelieve A. M., Astrahantseff, Kathy, Deubzer, Hedwig, De Wilde, Bram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971142/ https://www.ncbi.nlm.nih.gov/pubmed/31897843 http://dx.doi.org/10.1007/s00431-019-03545-y

Ejemplares similares

Meta-mining of copy number profiles of high-risk neuroblastoma tumors
por: Depuydt, Pauline, et al.
Publicado: (2018)

Cancer Gene Prioritization for Targeted Resequencing Using FitSNP Scores
por: Fieuw, Annelies, et al.
Publicado: (2012)

Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome
por: Van Paemel, Ruben, et al.
Publicado: (2020)

Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma
por: Lak, Nathalie S.M., et al.
Publicado: (2023)

N-Cadherin in Neuroblastoma Disease: Expression and Clinical Significance
por: Lammens, Tim, et al.
Publicado: (2012)

Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect
por: Arlt, Birte, et al.
Publicado: (2021)

CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23
por: Michels, Evi, et al.
Publicado: (2008)

From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma
por: Decaesteker, Bieke, et al.
Publicado: (2021)

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
por: Decock, Anneleen, et al.
Publicado: (2015)

The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness
por: Mus, Liselot M., et al.
Publicado: (2020)

No evidence for involvement of SDHD in neuroblastoma pathogenesis
por: De Preter, Katleen, et al.
Publicado: (2004)

Positional gene enrichment analysis of gene sets for high-resolution identification of overrepresented chromosomal regions
por: De Preter, Katleen, et al.
Publicado: (2008)

Case series on clinical applications of liquid biopsy in pediatric solid tumors: towards improved diagnostics and disease monitoring
por: Gelineau, Nina U., et al.
Publicado: (2023)

Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma
por: Lodrini, Marco, et al.
Publicado: (2017)

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes
por: Vandesompele, Jo, et al.
Publicado: (2002)

Correction: Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes
por: De Preter, Katleen, et al.
Publicado: (2007)

Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes
por: De Preter, Katleen, et al.
Publicado: (2006)

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
por: Decock, Anneleen, et al.
Publicado: (2012)

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome
por: Claeys, Shana, et al.
Publicado: (2017)

The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy
por: Van Roy, Nadine, et al.
Publicado: (2009)

Combined subtractive cDNA cloning and array CGH: an efficient approach for identification of overexpressed genes in DNA amplicons
por: De Preter, Katleen, et al.
Publicado: (2004)

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma
por: Cazes, Alex, et al.
Publicado: (2014)

Multiplex Amplicon Quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma
por: Kumps, Candy, et al.
Publicado: (2010)

Digital PCR-based evaluation of nucleic acid extraction kit performance for the co-purification of cell-free DNA and RNA
por: Deleu, Jill, et al.
Publicado: (2022)

Measurable impact of RNA quality on gene expression results from quantitative PCR
por: Vermeulen, Joëlle, et al.
Publicado: (2011)

Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes
por: Kumps, Candy, et al.
Publicado: (2013)

Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma
por: Cuperus, Roos, et al.
Publicado: (2009)

External oligonucleotide standards enable cross laboratory comparison and exchange of real-time quantitative PCR data
por: Vermeulen, Joëlle, et al.
Publicado: (2009)

RNA pre-amplification enables large-scale RT-qPCR gene-expression studies on limiting sample amounts
por: Vermeulen, Joëlle, et al.
Publicado: (2009)

In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors
por: Vanhauwaert, Suzanne, et al.
Publicado: (2018)

Publisher Correction: In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors
por: Vanhauwaert, Suzanne, et al.
Publicado: (2019)

Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma
por: Rihani, Ali, et al.
Publicado: (2015)

CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients
por: Rihani, Ali, et al.
Publicado: (2014)

Genes at the Crossroad of Primary Immunodeficiencies and Cancer
por: Derpoorter, Charlotte, et al.
Publicado: (2018)

MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma
por: Lodrini, Marco, et al.
Publicado: (2013)

ViVar: A Comprehensive Platform for the Analysis and Visualization of Structural Genomic Variation
por: Sante, Tom, et al.
Publicado: (2014)

MYCN transcriptionally represses CD9 to trigger an invasion-metastasis cascade in neuroblastoma
por: Fabian, Johannes, et al.
Publicado: (2015)

Evaluation of a marker independent isolation method for circulating tumor cells in esophageal adenocarcinoma
por: Philippron, Annouck, et al.
Publicado: (2021)

A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk Neuroblastoma
por: Barbieri, Eveline, et al.
Publicado: (2013)

The mutational landscape of MYCN, Lin28b and ALK(F1174L) driven murine neuroblastoma mimics human disease
por: De Wilde, Bram, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_quu518b5mjafj9jmu7cp44jg9g